Caribou Biosciences, Inc.
CRBU
$1.86
-$0.05-2.62%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 3.94M | 2.20M | 2.67M | 2.35M | 2.08M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 3.94M | 2.20M | 2.67M | 2.35M | 2.08M |
| Cost of Revenue | 23.82M | 22.40M | 1.30M | 1.74M | 30.46M |
| Gross Profit | -19.87M | -20.20M | 1.37M | 610.00K | -28.39M |
| SG&A Expenses | 8.58M | 9.20M | 10.40M | 9.74M | 10.49M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 32.39M | 31.60M | 38.10M | 45.27M | 40.95M |
| Operating Income | -28.45M | -29.40M | -35.43M | -42.91M | -38.88M |
| Income Before Tax | -27.04M | -27.55M | -54.10M | -39.99M | -35.50M |
| Income Tax Expenses | -550.00K | -- | -- | -- | -9.00K |
| Earnings from Continuing Operations | -26.49M | -27.55M | -54.10M | -39.99M | -35.49M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -26.49M | -27.55M | -54.10M | -39.99M | -35.49M |
| EBIT | -28.45M | -29.40M | -35.43M | -42.91M | -38.88M |
| EBITDA | -27.77M | -28.77M | -34.26M | -41.75M | -37.69M |
| EPS Basic | -0.28 | -0.30 | -0.58 | -0.43 | -0.39 |
| Normalized Basic EPS | -0.18 | -0.18 | -0.28 | -0.27 | -0.24 |
| EPS Diluted | -0.28 | -0.30 | -0.58 | -0.43 | -0.39 |
| Normalized Diluted EPS | -0.18 | -0.18 | -0.28 | -0.27 | -0.24 |
| Average Basic Shares Outstanding | 94.54M | 93.29M | 93.03M | 92.68M | 91.16M |
| Average Diluted Shares Outstanding | 94.54M | 93.29M | 93.03M | 92.68M | 91.16M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |